









市场行情
/
股票
/
nasdaq-sln
/

Silence Therapeutics PLC

SLN

6.450USD

0.000

收盘 12/22, 16:00（美东）报价延迟15分钟

304.66M总市值

亏损市盈率 TTM



Silence Therapeutics PLC

6.450

0.000

概览公司财务分析

概览

公司

财务

分析

关于 Silence Therapeutics PLC 公司

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Silence Therapeutics PLC简介



公司代码SLN

公司名称Silence Therapeutics PLC

上市日期Jan 05, 2010

CEOTooman (Craig A)

员工数量116

证券类型Depository Receipt

年结日Jan 05

公司地址72 Hammersmith Road

城市LONDON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编W14 8TH

电话442034576900

网址https://www.silence-therapeutics.com/

公司代码SLN

上市日期Jan 05, 2010

CEOTooman (Craig A)

Silence Therapeutics PLC公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Timothy (Tim) McInerney

Independent Director

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

Ms. Gem Hopkins

Head of IR and Corporate Communications

名称

名称/职务

职务

持股

持股变动

Mr. Timothy (Tim) McInerney

Independent Director

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United Kingdom

43.11M

99.67%

Germany

144.00K

0.33%

USA

0.00

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.91%

其他

54.55%

持股股东

占比

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

6.16%

Redmile Group, LLC

4.58%

Lombard Odier Asset Management (USA) Corp.

3.91%

其他

54.55%

股东类型

持股股东

占比

Individual Investor

24.38%

Investment Advisor

18.46%

Investment Advisor/Hedge Fund

9.97%

Venture Capital

3.35%

Hedge Fund

3.30%

Research Firm

3.11%

Private Equity

2.05%

Bank and Trust

0.03%

其他

35.34%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

138

19.95M

42.23%

-14.76M

2025Q2

131

33.68M

71.31%

-14.18M

2025Q1

133

31.94M

67.63%

-14.00M

2024Q4

128

31.43M

66.56%

-10.23M

2024Q3

111

35.93M

77.05%

-5.19M

2024Q2

34.94M

74.95%

-4.57M

2024Q1

35.43M

76.18%

+4.14M

2023Q4

30.21M

78.15%

-609.51K

2023Q3

32.62M

88.08%

+1.55M

2023Q2

31.78M

89.08%

+2.79M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Griffiths (Richard Ian)

11.51M

24.38%

+543.58K

+4.95%

Jun 25, 2025

TCG Crossover Management, LLC

3.03M

6.42%

Jun 30, 2025

Invus Public Equities Advisors, LLC

2.91M

6.16%

+121.61K

+4.36%

Jun 30, 2025

Redmile Group, LLC

2.16M

4.58%

-50.17K

-2.27%

Jun 30, 2025

Lombard Odier Asset Management (USA) Corp.

1.85M

3.92%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.13M

2.39%

-766.91K

-40.44%

Jun 30, 2025

Vivo Capital, LLC

1.11M

2.34%

Jun 30, 2025

Nantahala Capital Management, LLC

1.04M

2.21%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

970.13K

2.05%

-178.46K

-15.54%

Jun 30, 2025

Nextech Invest, Ltd.

952.40K

2.02%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.01%

ActivePassive International Equity ETF

iShares Biotechnology ETF

Tema Heart & Health ETF

Virtus LifeSci Biotech Clinical Trials ETF

占比0.87%

ProShares Ultra Nasdaq Biotechnology

占比0.03%

Invesco Nasdaq Biotechnology ETF

占比0.03%

SPDR S&P International Small Cap ETF

占比0.01%

ActivePassive International Equity ETF

占比0%

iShares Biotechnology ETF

占比0%

Tema Heart & Health ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Silence Therapeutics PLC的前五大股东是谁？



Silence Therapeutics PLC 的前五大股东如下：
Griffiths (Richard Ian)持有股份：11.51M，占总股份比例：24.38%。
TCG Crossover Management, LLC持有股份：3.03M，占总股份比例：6.42%。
Invus Public Equities Advisors, LLC持有股份：2.91M，占总股份比例：6.16%。
Redmile Group, LLC持有股份：2.16M，占总股份比例：4.58%。
Lombard Odier Asset Management (USA) Corp.持有股份：1.85M，占总股份比例：3.92%。